NO20074545L - GIP-analog og hybridpolypeptid med selekterbare egenskaper - Google Patents

GIP-analog og hybridpolypeptid med selekterbare egenskaper

Info

Publication number
NO20074545L
NO20074545L NO20074545A NO20074545A NO20074545L NO 20074545 L NO20074545 L NO 20074545L NO 20074545 A NO20074545 A NO 20074545A NO 20074545 A NO20074545 A NO 20074545A NO 20074545 L NO20074545 L NO 20074545L
Authority
NO
Norway
Prior art keywords
disorders
type
selectable properties
insulin
hybrid polypeptide
Prior art date
Application number
NO20074545A
Other languages
English (en)
Inventor
Odile Esther Levy
Michael R Hanley
Carolyn M Jodka
Diana Y Lewis
Christopher J Soares
Suomitra S Ghosh
Souza Lawrence J D
David G Parkes
Christine M Mack
Ved Srivastava
Samuel Janssen
Alain D Baron
Andrew A Young
Richard A Pittner
Mary Erickson
Original Assignee
Amylin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc
Publication of NO20074545L publication Critical patent/NO20074545L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

Foreliggende oppfinnelse gjelder generelt nye GIP-analoger og GIP-hybridpolypeptider med valgbare egenskaper som er anvendbare som midler for behandling og forebyggelse av metabolske sykdommer og forstyrrelser, f.eks. sykdommer og forstyrrelser som kan lindres ved kontroll av glukosenivået i plasma, insulinnivået og/eller insulinsekresjonen, positive inotropiske virkninger, reduksjon av katabolske virkninger og redusert magetømming. Slike tilstander og forstyrrelser omfatter, men er ikke begrenset til, hypertensjon, dyslipidemi, hjerte-karsykdom, spiseforstyrrelser, kritisk pleie, insulinresistens, fedme og diabetes mellittus av hvilken som helst type, innbefattet type 1, type 2 og svangerskapsdiabetes.
NO20074545A 2005-02-11 2007-09-07 GIP-analog og hybridpolypeptid med selekterbare egenskaper NO20074545L (no)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US65164705P 2005-02-11 2005-02-11
US65266205P 2005-02-11 2005-02-11
US65343305P 2005-02-15 2005-02-15
US70736905P 2005-08-11 2005-08-11
US70724405P 2005-08-11 2005-08-11
US70932005P 2005-08-17 2005-08-17
US70931605P 2005-08-17 2005-08-17
PCT/US2006/005020 WO2006086769A2 (en) 2005-02-11 2006-02-10 Gip analog and hybrid polypeptides with selectable properties

Publications (1)

Publication Number Publication Date
NO20074545L true NO20074545L (no) 2007-11-09

Family

ID=36588963

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074545A NO20074545L (no) 2005-02-11 2007-09-07 GIP-analog og hybridpolypeptid med selekterbare egenskaper

Country Status (14)

Country Link
US (2) US8404637B2 (no)
EP (3) EP2390264A1 (no)
JP (1) JP2008530130A (no)
KR (1) KR20070115947A (no)
AU (1) AU2006213607A1 (no)
BR (1) BRPI0606992A2 (no)
CA (1) CA2597649A1 (no)
EA (1) EA011653B1 (no)
IL (1) IL185563A0 (no)
MX (1) MX2007009760A (no)
NO (1) NO20074545L (no)
NZ (1) NZ561361A (no)
SG (1) SG159551A1 (no)
WO (1) WO2006086769A2 (no)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6048625A (ja) * 1983-08-29 1985-03-16 Anritsu Corp ２重スーパヘテロダイン受信機
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
CN101128487B (zh) * 2004-12-02 2012-10-10 杜门蒂斯有限公司 靶向血清白蛋白和glp-1或pyy的双特异性结构域抗体
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
KR20070115947A (ko) 2005-02-11 2007-12-06 아밀린 파마슈티칼스, 인크. 선택가능한 특성들을 가지는 ｇｉｐ 유사체 및 하이브리드폴리펩타이드
WO2007022123A2 (en) * 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
WO2007014051A2 (en) * 2005-07-22 2007-02-01 Amylin Pharmaceuticals, Inc. Use of amylin and amylin agonists as cardioprotective or myoprotective agents
CA2913805A1 (en) 2005-11-07 2007-05-18 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
CA2638800A1 (en) * 2006-02-22 2007-09-07 Merck & Co., Inc. Oxyntomodulin derivatives
JP2009532422A (ja) * 2006-04-03 2009-09-10 ノボ・ノルデイスク・エー／エス Ｇｌｐ−１ペプチドアゴニスト
EP2359808B1 (en) 2006-08-09 2013-05-22 Intarcia Therapeutics, Inc Osmotic delivery systems and piston assemblies
US8497240B2 (en) * 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
WO2008021560A2 (en) * 2006-08-17 2008-02-21 Amylin Pharmaceuticals, Inc. Dpp-iv resistant gip hybrid polypeptides with selectable properties
RU2477286C2 (ru) 2007-01-05 2013-03-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМ ЗНАЧЕНИЕМ pH
CA2677932A1 (en) 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
WO2008133908A2 (en) 2007-04-23 2008-11-06 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
CN101541957B (zh) * 2007-07-20 2013-08-14 梅约医学教育与研究基金会 利尿钠多肽
WO2009033690A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Bfgf (119-126) for therapeutic applications
KR20100056507A (ko) * 2007-09-11 2010-05-27 몬도바이오테크 래보래토리즈 아게 치료제로서의 펩티드 ｐｒｏ－ｇｌｙ－ｔｈｒ－ｃｙｓ－ｇｌｕ－ｉｌｅ－ｃｙｓ－ａｌａ－ｔｙｒ－ａｌａ－ａｌａ－ｃｙｓ－ｔｈｒ－ｇｌｙ－ｃｙｓ의 용도
JP2010539002A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト ウロジラチンの治療剤としての使用
GB0721131D0 (en) * 2007-10-27 2007-12-05 Univ Belfast "Peptide and users thereof"
ES2509883T3 (es) 2007-10-30 2014-10-20 Indiana University Research And Technology Corporation Antagonistas de glucagón
MX2010004298A (es) * 2007-10-30 2010-05-03 Univ Indiana Res & Tech Corp Compuestos que exhiben actividad antagonista de glucagon y agonista de glp-1.
US8710002B2 (en) * 2007-11-23 2014-04-29 Michael Rothkopf Methods of enhancing diabetes resolution
EP2249853A4 (en) * 2008-01-30 2012-12-26 Univ Indiana Res & Tech Corp ESTER BASED PEPTIDE PRODRUGS
CA2726861C (en) * 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
CA2758023A1 (en) 2008-04-09 2009-10-15 Cornell University Commensal bacteria as signal mediators within a mammalian host
CN102105159B (zh) * 2008-06-17 2015-07-08 印第安纳大学研究及科技有限公司 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症
AR072160A1 (es) 2008-06-17 2010-08-11 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
US8450270B2 (en) * 2008-06-17 2013-05-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
AU2009280021B2 (en) * 2008-08-07 2012-10-04 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide (GIP) modified at N-terminal
ES2574835T3 (es) * 2008-08-07 2016-06-22 Ipsen Pharma S.A.S. Análogos del polipéptido insulinotrópico dependiente de glucosa
WO2010016940A2 (en) * 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide
KR20110043687A (ko) * 2008-08-07 2011-04-27 입센 파마 에스.에이.에스 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드의 절단형 유사체
PE20120332A1 (es) 2008-12-19 2012-04-14 Univ Indiana Res & Tech Corp Profarmacos de peptido de la superfamilia de glucagon basado en amida
JP5576694B2 (ja) * 2009-04-10 2014-08-20 花王株式会社 Ｇｉｐ上昇抑制剤
EP2443146B1 (en) 2009-06-16 2016-10-05 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
WO2011006644A2 (en) * 2009-07-15 2011-01-20 Lonza Ltd Process for the production of exenatide and of an exenatide analogue
RU2547990C2 (ru) 2009-09-28 2015-04-10 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
EP2504021A4 (en) * 2009-11-23 2013-05-15 Amylin Pharmaceuticals Llc Polypeptide conjugate
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
KR20120123443A (ko) * 2010-01-27 2012-11-08 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트
US20130157954A1 (en) * 2010-05-11 2013-06-20 Nps Pharmaceuticals, Inc. Methods for treatment or prophylaxis of kidney or liver dysfunction
MX2012013001A (es) 2010-05-13 2013-02-26 Univ Indiana Res & Tech Corp Peptidos de la superfamilia de glucagon que presentan actividad del receptor nuclear de hormonas.
JP6050746B2 (ja) 2010-05-13 2016-12-21 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation Ｇタンパク質共役受容体活性を示すグルカゴンスーパーファミリーのペプチド
EP2588126A4 (en) 2010-06-24 2015-07-08 Univ Indiana Res & Tech Corp AMID-BASED GLUCAGON SUPERFAMILY PEPTIDE PRODRUGS
BR112013008957A2 (pt) 2010-10-15 2019-09-24 Univ Cornell composições e métodos para tratamento de doenças endócrinas, gastrointestinais ou autoimunes
US9023986B2 (en) 2010-10-25 2015-05-05 Hoffmann-La Roche Inc. Glucose-dependent insulinotropic peptide analogs
US8507428B2 (en) 2010-12-22 2013-08-13 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US20120277155A1 (en) 2011-02-25 2012-11-01 Medtronic, Inc. Therapy for kidney disease and/or heart failure
WO2012138867A2 (en) 2011-04-07 2012-10-11 The Board Of Trustees Of The Leland Stanford Junior University Long-acting peptide analogs
KR20140045433A (ko) * 2011-05-25 2014-04-16 아밀린 파마슈티칼스, 엘엘씨. 아밀린 펩티드 및 그의 유도체 및 용도
UA126465C2 (uk) * 2011-06-10 2022-10-12 Ханмі Сайенс Ко., Лтд. Пептид, що має активність оксинтомодуліну, та фармацевтична композиція для лікування ожиріння, яка його містить
US9453062B2 (en) 2011-06-10 2016-09-27 Beijing Hanmi Pharmaceutical Co., Ltd. Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
RU2607365C2 (ru) 2011-06-17 2017-01-10 Ханми Сайенс Ко., Лтд. Конъюгат, содержащий оксинтомодулин и фрагмент иммуноглобулина, и его применение
RS56173B1 (sr) 2011-06-22 2017-11-30 Univ Indiana Res & Tech Corp Koagonisti receptora za glukagon/glp-1 receptora
KR20140043793A (ko) 2011-06-22 2014-04-10 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/glp-1 수용체 공동-작용물질
RU2514093C2 (ru) * 2011-08-09 2014-04-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Сибирский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО СибГМУ Минздравсоцразвития России) Средство для инъекционной терапии гастроэзофагеальной рефлюксной болезни
EP2750697A4 (en) 2011-09-02 2015-03-25 Medtronic Inc CHIMERIC NATRIURETIC PEPTIDE COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
JP6324315B2 (ja) 2011-11-17 2018-05-16 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ グルココルチコイド受容体の活性を示すグルカゴンスーパーファミリーのペプチド
WO2013103896A1 (en) 2012-01-06 2013-07-11 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
KR101855242B1 (ko) 2012-01-26 2018-05-09 크리스토퍼 제이. 소레스 펩타이드 호르몬의 칼시토닌 cgrp 패밀리의 펩타이드 길항제 및 그의 용도
CN104583232B (zh) 2012-06-21 2018-04-13 印第安纳大学研究及科技有限公司 展现gip受体活性的胰高血糖素类似物
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
WO2014073842A1 (en) 2012-11-06 2014-05-15 Hanmi Pharm. Co., Ltd. Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
AU2013366692B2 (en) 2012-12-21 2017-11-23 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
JP6538645B2 (ja) 2013-03-14 2019-07-03 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン‐インクレチン複合物
SI3004155T1 (sl) 2013-05-28 2022-02-28 Takeda Pharmaceutical Company Limited Peptidna spojina
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
ES2685987T3 (es) 2014-09-05 2018-10-15 University Of Copenhagen Análogos de péptidos gip
TWI802396B (zh) 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
CN108271356A (zh) 2014-09-24 2018-07-10 印第安纳大学研究及科技有限公司 肠降血糖素-胰岛素缀合物
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
KR102620911B1 (ko) * 2014-10-29 2024-01-05 질랜드 파마 에이/에스 Gip 효능제 화합물 및 방법
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
RU2730996C2 (ru) 2015-06-03 2020-08-26 Интарсия Терапьютикс, Инк. Системы установки и извлечения имплантата
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
UA127495C2 (uk) 2015-12-23 2023-09-13 Амджен Інк. Виділений антигензв'язуючий білок, який специфічно зв'язується з поліпептидом рецептора шлункового інгібіторного пептиду (gipr) людини, та фармацевтична композиція, яка його містить
EP3400237A4 (en) 2016-01-04 2020-03-04 Adepthera LLC Peptide analogs
US10893832B2 (en) * 2016-01-13 2021-01-19 Tufts Medical Center, Inc. Predictive instrument to identify patients for use of pharmacological cardiac metabolic support
WO2017139154A1 (en) 2016-02-09 2017-08-17 Adepthera Llc Dosing and use of long-acting clr/ramp agonists
KR102574993B1 (ko) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
JP6995042B2 (ja) 2016-05-24 2022-02-04 武田薬品工業株式会社 ペプチド化合物
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
CA3035561A1 (en) 2016-09-02 2018-03-08 Christopher J. Soares Use of cgrp receptor antagonists in neuroprotection and neurological disorders
JP7286542B2 (ja) 2017-01-03 2023-06-05 インターシア セラピューティクス，インコーポレイティド Ｇｌｐ－１受容体アゴニストの持続的投与及び薬物の同時投与を含む方法
IL313587A (en) 2017-01-17 2024-08-01 Amgen Inc Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)
WO2018175924A1 (en) 2017-03-24 2018-09-27 The Broad Institute, Inc. Methods and compositions for regulating innate lymphoid cell inflammatory responses
JOP20190211A1 (ar) 2017-03-31 2019-09-15 Takeda Pharmaceuticals Co ببتيد منشط لمستقبل gip
KR102743887B1 (ko) 2017-05-31 2024-12-19 유니버시티 오브 코펜하겐 장기-작용성 gip 펩타이드 유사체
EA201992502A1 (ru) 2017-06-20 2020-04-22 Эмджен Инк. Способ лечения или уменьшения интенсивности метаболических нарушений с применением белков, связывающих рецептор гастроингибиторного пептида (gipr), в комбинации с агонистами glp-1
EP3642238A1 (en) 2017-06-21 2020-04-29 Amgen Inc. Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (gipr)/glp-1 receptor agonist fusion proteins
SG11201912433YA (en) 2017-06-29 2020-01-30 Ureka Sarl Pro-drug peptide with improved pharmaceutical properties
WO2019005623A1 (en) 2017-06-30 2019-01-03 Adepthera Llc PEPTIDE ANALOGS
EP3856339A1 (en) * 2018-09-24 2021-08-04 Takeda Pharmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
SG11202105586YA (en) * 2018-12-03 2021-06-29 Antag Therapeutics Aps Modified gip peptide analogues
WO2020148317A1 (en) 2019-01-18 2020-07-23 Ureka Sarl Peptide-oligourea hybrid compounds
TWI799680B (zh) * 2019-01-29 2023-04-21 美商美國禮來大藥廠 製備gip/glp1雙重促效劑之方法
EP3934677A4 (en) 2019-03-13 2022-11-16 University of Virginia Patent Foundation COMPOSITIONS AND METHODS TO PROMOTE ISLAND VIABILITY AND INCREASE INSULINE SECRETION
US20250346647A2 (en) * 2019-12-03 2025-11-13 Antag Therapeutics Aps Optimized GIP Peptide Analogues
CN115335395A (zh) * 2020-03-25 2022-11-11 武田药品工业株式会社 Gip受体激动剂肽化合物的qd给药及其用途
EP4138780A4 (en) * 2020-04-20 2024-05-15 I2O Therapeutics, Inc. Use of human amylin analog polypeptides for providing superior glycemic control to type 1 diabetics
AR124295A1 (es) 2020-12-18 2023-03-15 Lilly Co Eli Agonistas duales del receptor de amilina y calcitonina y usos de los mismos
CA3221661A1 (en) * 2021-06-10 2022-12-15 Alexander HOVARD SPARRE-ULRICH Treatment of obesity and obesity-related disorders
JP2024525843A (ja) * 2021-07-16 2024-07-12 ぺプ２タンゴ セラピューティクス インコーポレイテッド マルチアゴニストペプチドを含む組成物並びに製造及び使用方法
AU2024313859A1 (en) * 2023-06-22 2026-01-15 Slbigen Inc. Novel bispecific fusion protein and use thereof
TW202540155A (zh) 2023-11-30 2025-10-16 丹麥商諾佛 儂迪克股份有限公司 Glp-1、gip及澱粉素受體之三重促效劑
EP4582441A3 (en) * 2023-12-12 2025-09-10 Amide Technologies Multimeric polypeptides and uses thereof
CN120040558A (zh) * 2024-03-19 2025-05-27 深圳湾实验室 多肽或其类似物及其应用

Family Cites Families (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US206903A (en) 1878-08-13 Improvement in cultivators
US3490597A (en) 1966-07-22 1970-01-20 Purolator Products Inc Cover plate for spin-on-filter
DE3065460D1 (en) * 1979-07-28 1983-12-08 Beecham Group Plc Benzocycloheptapyrrolealkanoic acids and their derivatives, processes for their preparation and pharmaceutical compositions containing them
EP0047921A1 (de) 1980-09-15 1982-03-24 Menzel GmbH. + Co. Verfahren zum Belüften einer Flüssigkeit, insbesondere Abwasser und Vorrichtung zur Durchführung des Verfahrens
US4401593A (en) 1982-02-12 1983-08-30 Armour Pharmaceutical Company Glycine - 8 calcitonin
US4397780A (en) 1982-02-12 1983-08-09 Armour Pharmaceutical Company Leucine22 -calcitonin
CA1187523A (en) 1982-02-22 1985-05-21 Edgar H. Lais Pulley operated exercising device
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4414149A (en) 1983-03-04 1983-11-08 Armour Pharmaceutical Company Glycine8 -D-arginine24 calcitonin
US4495097A (en) 1983-04-04 1985-01-22 Armour Pharmaceutical Company Des-serine2 -glycine8 calcitonin
US4497731A (en) 1983-04-04 1985-02-05 Armour Pharmaceutical Company Glycine 8-des-tyrosine 22 calcitonin
US5188666A (en) 1983-06-30 1993-02-23 Boccardo Victor N Paint removing compositions and methods for the manufacture and use thereof
US4597900A (en) 1983-08-22 1986-07-01 Armour Pharmaceutical Co. Des2 -glycine8 -des22 -calcitonin
US4537716A (en) 1983-12-05 1985-08-27 Armour Pharmaceutical Co. Des-serine2 or des-glycine2 -leucine22 calcitonin
US4604238A (en) 1984-12-10 1986-08-05 Armour Pharmaceutical Company Analogs of calcitonin
US4606856A (en) 1985-03-18 1986-08-19 Seyler Jay K [Des-1-amino, 8-glycine]calcitonin
US4652627A (en) 1985-08-16 1987-03-24 Kempe Tomas G Calcitonin analogs with C-terminal D-amino acid substituents
US4687839A (en) 1985-12-23 1987-08-18 Kempe Tomas G Calcitonin gene related peptide analogs with C-terminal D-amino acid substituents
US4697002A (en) 1985-12-23 1987-09-29 Kempe Tomas G Calcitonin gene related peptide analogs with amino acid subdstituents at the penultimate position 36
AU3342689A (en) * 1988-03-24 1989-10-16 Igen Incorporated Luminescent chimeric proteins
KR0133561B1 (ko) 1988-05-13 1998-04-21 스티븐 엠. 오드레 과립구 군체 자극인자의 정제방법
CA1339210C (en) 1988-05-31 1997-08-05 John Lewicki Recombinant techniques for production of novel natriuretic and vasodilator peptides
US5114923A (en) 1988-05-31 1992-05-19 California Biotechnology Inc. Recombinant techniques for production of novel natriuretic and vasodilator peptides
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
ATE164852T1 (de) 1990-01-24 1998-04-15 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
JPH04145099A (ja) 1990-10-05 1992-05-19 Sanwa Kagaku Kenkyusho Co Ltd Ｇｉｐ様活性を有するポリペプチド誘導体及びその用途
HUT69963A (en) 1990-12-13 1995-09-28 Upjohn Co Non-naturally-occuring fusion proteins and process for preparing them
US5234906A (en) * 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
DE69232453T2 (de) 1991-07-08 2002-07-18 Denso Corp., Kariya Thermischer Durchflussmesser
US5445781A (en) 1991-08-28 1995-08-29 Centro Sviluppo Settori Impiego S.R.L. Process for the injection molding of non-precatalyzed polymerizable resins at high-pressure and flow
US5509305A (en) 1992-02-12 1996-04-23 Daniel Industries, Inc. Closely coupled, dual turbine volumetric flow meter
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
AU672790B2 (en) 1992-07-15 1996-10-17 Novartis Ag Variants of parathyroid hormone and its fragments
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US6077822A (en) * 1993-09-14 2000-06-20 Dumex-Alpharma A/S Drug salts
CA2137206A1 (en) 1993-12-09 1995-06-10 John A. Galloway Glucagon-like insulinotropic peptides, compositions and methods
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
EP1132091A1 (en) 1994-01-24 2001-09-12 The General Hospital Corporation Treatment for diabetes
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
US5827734A (en) 1995-01-20 1998-10-27 University Of Washington Materials and methods for determining ob protein in a biological sample
US5521283A (en) * 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
US5532336A (en) * 1995-01-31 1996-07-02 Eli Lilly And Company Anti-obesity proteins
US5789379A (en) 1995-04-14 1998-08-04 Allelix Biopharmaceutical Inc. Glucagon-like peptide-2 analogs
US5739106A (en) * 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
HUP9802609A2 (hu) 1995-06-30 1999-03-29 Eli Lilly And Co. A diabetes kezelésére szolgáló eljárás
US6852690B1 (en) * 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
DE19530865A1 (de) 1995-08-22 1997-02-27 Michael Dr Med Nauck Wirkstoff sowie Mittel zur parenteralen Ernährung
WO1997015322A1 (en) 1995-10-25 1997-05-01 The Regents Of The University Of California Methods for restoring or enhancing reproductive function in reproductively impaired hosts
DE19546405A1 (de) 1995-12-12 1997-06-19 Busch Dieter & Co Prueftech Verfahren zum gegenseitigen Ausrichten von Körpern und Lagemeßsonde hierfür
WO1997027286A1 (en) 1996-01-23 1997-07-31 Progenitor, Inc. Methods for using the obese gene and its gene product to stimulate hematopoietic development
US5912007A (en) 1996-02-29 1999-06-15 Warner-Lambert Company Delivery system for the localized administration of medicaments to the upper respiratory tract and methods for preparing and using same
DE122010000020I1 (de) * 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
KR20000016402A (ko) 1996-06-06 2000-03-25 피터 기딩스 렙틴(ob단백질)의 프레그먼트
US5686511A (en) 1996-06-28 1997-11-11 The Valspar Corporation Esterifying epoxy resin with carboxyl polymer and quenching
WO1998001224A1 (fr) 1996-07-04 1998-01-15 Nikolai Ivanovich Kuchersky Broyeur centrifuge
ATE493998T1 (de) 1996-08-08 2011-01-15 Amylin Pharmaceuticals Inc Pharmazeutische zusammensetzung mit einem exendin-4-peptid
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
WO1998012224A1 (en) 1996-09-20 1998-03-26 Hoechst Aktiengesellschaft Use of leptin antagonists for treating insulin resistance in type ii diabetes
WO1998018486A1 (en) 1996-10-25 1998-05-07 Icogen Corporation Use of leptin to stimulate hematopoiesis
US7091183B1 (en) 1996-12-03 2006-08-15 Boston Medical Center Corporation Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP)
WO1998024464A1 (en) 1996-12-03 1998-06-11 Trustees Of Boston University Specific antagonists for glucose-dependent insulinotropic polypeptide (gip)
DE122007000044I2 (de) 1997-01-07 2011-05-05 Amylin Pharmaceuticals Inc Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
AU6656098A (en) 1997-02-25 1998-09-09 Eli Lilly And Company Treatment of infertility with leptin receptor ligands
US5846937A (en) * 1997-03-03 1998-12-08 1149336 Ontario Inc. Method of using exendin and GLP-1 to affect the central nervous system
DE69840146D1 (de) 1997-03-14 2008-12-04 Univ California Fluoreszenzprotein-sensoren zur erkennung von analyten
US5998204A (en) * 1997-03-14 1999-12-07 The Regents Of The University Of California Fluorescent protein sensors for detection of analytes
US5981488A (en) 1997-03-31 1999-11-09 Eli Lillly And Company Glucagon-like peptide-1 analogs
IL120733A0 (en) 1997-04-29 1997-08-14 Yeda Res & Dev Leptin as an inhibitor of cell proliferation
WO1998055139A1 (en) 1997-06-06 1998-12-10 Smithkline Beecham Plc Use of leptin antagonists for the treatment of diabetes
US7910548B2 (en) 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
ES2293688T5 (es) 1997-08-08 2011-05-04 Amylin Pharmaceuticals, Inc. Nuevos compuestos análogos de la exendina.
ATE383867T1 (de) 1997-11-14 2008-02-15 Amylin Pharmaceuticals Inc Neuartige exendin agonisten
MXPA00004670A (es) 1997-11-14 2003-07-14 Amylin Pharmaceuticals Inc Compuestos agonistas de exendina novedosos.
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
EP1119625B1 (en) 1998-10-07 2005-06-29 Medical College Of Georgia Research Institute, Inc. Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US7745216B2 (en) 1999-02-10 2010-06-29 Curis, Inc. Methods and reagents for treating glucose metabolic disorders
US6921748B1 (en) 1999-03-29 2005-07-26 Uutech Limited Analogs of gastric inhibitory polypeptide and their use for treatment of diabetes
DE19921537A1 (de) 1999-05-11 2000-11-23 Dieter Hoersch Verfahren zur Induzierung von Zellwachstum durch Verwendung geeigneter Mittel
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6849714B1 (en) * 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6162260A (en) 1999-05-24 2000-12-19 Novo Nordisk Biochem North America, Inc. Single-bath biopreparation and dyeing of textiles
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US6528486B1 (en) * 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US6407211B1 (en) 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
US6380398B2 (en) 2000-01-04 2002-04-30 Novo Nordisk A/S Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV
WO2001051078A1 (en) 2000-01-10 2001-07-19 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia
US6734166B1 (en) 2000-02-08 2004-05-11 North Carolina State University Method of reducing aluminum levels in the central nervous system
JP4237375B2 (ja) 2000-03-31 2009-03-11 アスビオファーマ株式会社 虚血性疾患の処置又は予防に用いる医薬組成物
US6602997B2 (en) 2000-04-27 2003-08-05 Shin-Etsu Bio, Inc. Whole cell and cell-debris polysaccharide
KR20020097236A (ko) * 2000-04-27 2002-12-31 바이오네브라스카, 인코포레이티드 타입-2 당뇨병, 내당능 장애, 또는 공복 혈당 장애에 대한감수성을 검출하기 위한 위억제성 폴리펩티드 진단 시험
AU5675701A (en) 2000-05-16 2001-11-26 Sanwa Kagaku Kenkyusho Co Agents for preventing or ameliorating insulin resistance and/or obesity
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
CN1454214A (zh) 2000-08-02 2003-11-05 赛莱技术公司 具有增高功效的修饰生物肽
US6296842B1 (en) 2000-08-10 2001-10-02 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
US6916492B2 (en) 2001-03-30 2005-07-12 Council Of Scientific & Industrial Research Natural nontoxic multicolor fluorescent protein dye from a marine invertebrate, compositions containing the said dye and its uses
ATE408414T1 (de) 2001-07-31 2008-10-15 Us Gov Health & Human Serv Glp 1 exendin 4 peptidanaloga und deren verwendungen
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
CN100350968C (zh) 2001-09-24 2007-11-28 皇家创新有限公司 饮食行为的改进
US7317000B2 (en) * 2001-12-02 2008-01-08 Novo Nordisk A/S Glucose-dependent insulins
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
EP1474163A2 (en) 2002-01-10 2004-11-10 Imperial College Innovations Limited Modification of feeding behavior
US20030232761A1 (en) 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
ATE550344T1 (de) * 2002-05-24 2012-04-15 Medtronic Inc Verfahren zur spaltung von polypeptiden
US6710040B1 (en) 2002-06-04 2004-03-23 Pfizer Inc. Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
WO2003103572A2 (en) 2002-06-04 2003-12-18 Eli Lilly And Company Modified glucagon-like peptide-1 analogs
WO2003103697A2 (en) 2002-06-11 2003-12-18 Cell Therapeutics Scandinavia Ab Use of compounds having gip activity for the treatment of disorders associated with abnormal loss of cells and/or for the treatment of obesity
WO2003105763A2 (en) 2002-06-14 2003-12-24 Amylin Pharmaceuticals, Inc. Prevention and/or treatment of inflammatory bowel disease using pyy or agonists thereof
BR0311843A (pt) 2002-06-15 2005-03-15 Enteromed Inc Métodos para prevenir, inibir, tratar ou reduzir esteatose hepática não- alcoólica em um animal e para prevenir o desenvolvimento e/ou a reversão do processo de nafld em um animal
AU2003283004A1 (en) 2002-10-22 2004-05-13 Waratah Pharmaceuticals, Inc. Treatment of diabetes
AU2003290563A1 (en) 2002-10-31 2004-05-25 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US7192922B2 (en) 2002-11-19 2007-03-20 Allegheny-Singer Research Institute Method of treating left ventricular dysfunction
US6831394B2 (en) 2002-12-11 2004-12-14 General Electric Company Backing material for micromachined ultrasonic transducer devices
US20040209803A1 (en) 2002-12-19 2004-10-21 Alain Baron Compositions for the treatment and prevention of nephropathy
EP1610811A4 (en) 2002-12-17 2008-03-26 Amylin Pharmaceuticals Inc PREVENTION AND TREATMENT OF CARDIAC ARRHYTHMIAS
WO2004067548A2 (en) 2003-01-31 2004-08-12 Theratechnologies Inc. Chemically modified metabolites of regulatory peptides and methods of producing and using same
EP1626981A4 (en) 2003-03-04 2006-11-22 Biorexis Pharmaceutical Corp PROTEINS PROTECTED AGAINST DIPEPTIDYLPEPTIDASE
CA2518465A1 (en) 2003-03-25 2004-10-14 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
ATE549028T1 (de) 2003-05-15 2012-03-15 Tufts College Stabile analoga von glp-1
NZ579621A (en) 2004-02-11 2011-03-31 Amylin Pharmaceuticals Inc Hybrid polypeptides with selectable properties
ITRM20040105A1 (it) 2004-02-27 2004-05-27 Tecnogen Scpa Anticorpo monoclonale antitenascina umana.
KR20070115947A (ko) 2005-02-11 2007-12-06 아밀린 파마슈티칼스, 인크. 선택가능한 특성들을 가지는 ｇｉｐ 유사체 및 하이브리드폴리펩타이드
WO2007022123A2 (en) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
JP2009510999A (ja) 2005-07-29 2009-03-19 エーエムプロテイン コーポレイション キメラ治療剤
WO2008021560A2 (en) 2006-08-17 2008-02-21 Amylin Pharmaceuticals, Inc. Dpp-iv resistant gip hybrid polypeptides with selectable properties
JP6226510B2 (ja) 2012-01-27 2017-11-08 キヤノン株式会社 画像処理システム、処理方法及びプログラム
ITMI20130325A1 (it) 2013-03-05 2014-09-06 Telecom Italia Spa Metodo per misurare e monitorare il livello di accesso a dati personali generati da risorse di un dispositivo d'utente
US9816387B2 (en) 2014-09-09 2017-11-14 United Technologies Corporation Attachment faces for clamped turbine stator of a gas turbine engine
CA2914090C (en) 2015-03-31 2023-08-01 Allen-Vanguard Corporation Frequency and time domain streaming receiver
US9714199B2 (en) 2015-09-17 2017-07-25 I P Creations Limited Concealed amalgamated explosive neutralizer and method of manufacture

Also Published As

Publication number Publication date
EA011653B1 (ru) 2009-04-28
EP2390264A1 (en) 2011-11-30
US8404637B2 (en) 2013-03-26
AU2006213607A1 (en) 2006-08-17
US20130196913A1 (en) 2013-08-01
JP2008530130A (ja) 2008-08-07
NZ561361A (en) 2010-02-26
EP2392595A1 (en) 2011-12-07
WO2006086769A2 (en) 2006-08-17
IL185563A0 (en) 2008-01-06
US9133260B2 (en) 2015-09-15
EA200701704A1 (ru) 2008-02-28
MX2007009760A (es) 2007-11-07
CA2597649A1 (en) 2006-08-17
BRPI0606992A2 (pt) 2009-07-28
KR20070115947A (ko) 2007-12-06
WO2006086769A3 (en) 2006-11-02
SG159551A1 (en) 2010-03-30
EP1853627A2 (en) 2007-11-14
US20090036364A1 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
NO20074545L (no) GIP-analog og hybridpolypeptid med selekterbare egenskaper
WO2007022123A3 (en) Hybrid polypeptides with selectable properties
WO2005077072A3 (en) Hybrid polypeptides with selectable properties
WO2008021560A3 (en) Dpp-iv resistant gip hybrid polypeptides with selectable properties
MX2026002524A (es) Compuestos agonistas de gipr
EA200800548A1 (ru) Гибридные полипептиды с селектируемыми свойствами
WO2007104789A3 (en) Amylin derivatives
WO2010029089A3 (en) Combination therapy for the treatment of diabetes and related conditions
WO2007112069A3 (en) Endothelin and endothelin receptor agonists in the treatment of metabolic diseases
WO2010123930A3 (en) Chemosensory receptor ligand-based therapies
WO2011127304A3 (en) Methods of treating an overweight subject
GEP20146056B (en) Acylated glucagon analogues
ZA200903952B (en) Bicyclic compounds and use as antidiabetics
WO2008055940A8 (en) Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions
WO2007028633A3 (en) Treatment of diabetes related obesity
UA104605C2 (uk) Аналоги глюкагону
WO2010049678A3 (en) Treatment of energy utilization diseases
WO2012054526A3 (en) Chemosensory receptor ligand-based therapies
WO2009042922A3 (en) Peptide-peptidase inhibitor conjugates and methods of making and using same
WO2006012577A3 (en) Quinazolinone derivatives useful for the regulation of glucose homeostasis and food intake
SA522432563B1 (ar) نظير ببتيد أوكسينتو موديولين معالج بأسيل
WO2012054528A3 (en) Chemosensory receptor ligand-based therapies
WO2012054530A3 (en) Chemosensory receptor ligand-based therapies
EP2330125A3 (en) Hybrid polypeptides with selectable properties
WO2016168388A3 (en) Therapies for obesity, diabetes and related indications

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application